Amgen Will Hand Over $71 Million to Settle Drug Promotion Claims

Published: Aug 20, 2015

Aug 18 (Reuters) - Amgen Inc has reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that the biotechnology company promoted its popular Enbrel and Aranesp drugs for uses not approved by the federal Food and Drug Administration.

The settlement was announced by several state attorneys general on Tuesday.

Enbrel is used to treat moderate to severe plaque psoriasis, while Aranesp is used to treat certain forms of anemia.

Help employers find you! Check out all the jobs and post your resume.

Back to news